INTELLIA THERAPEUTICS INC's ticker is NTLA and the CUSIP is 45826J105. A total of 299 filers reported holding INTELLIA THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 1.39 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $9,874,578 | -59.0% | 312,289 | -47.1% | 0.00% | -40.0% |
| Q2 2023 | $24,086,625 | +66.4% | 590,648 | +52.0% | 0.01% | +66.7% |
| Q1 2023 | $14,479,470 | +17.5% | 388,502 | +10.0% | 0.00% | 0.0% |
| Q4 2022 | $12,318,089 | -53.0% | 353,055 | -24.6% | 0.00% | -57.1% |
| Q3 2022 | $26,219,000 | +68.1% | 468,526 | +55.5% | 0.01% | +75.0% |
| Q2 2022 | $15,597,000 | -22.4% | 301,341 | +8.9% | 0.00% | +33.3% |
| Q1 2022 | $20,106,000 | -62.4% | 276,679 | -38.9% | 0.00% | +50.0% |
| Q4 2021 | $53,522,000 | +8.4% | 452,650 | +23.0% | 0.00% | -71.4% |
| Q3 2021 | $49,381,000 | -59.1% | 368,101 | -50.7% | 0.01% | -58.8% |
| Q2 2021 | $120,858,000 | +376.4% | 746,452 | +136.1% | 0.02% | +325.0% |
| Q1 2021 | $25,370,000 | -5.4% | 316,125 | -35.9% | 0.00% | +33.3% |
| Q4 2020 | $26,828,000 | +457.5% | 493,170 | +103.8% | 0.00% | +200.0% |
| Q3 2020 | $4,812,000 | +23.4% | 242,038 | +30.4% | 0.00% | – |
| Q2 2020 | $3,901,000 | +94.9% | 185,577 | +13.4% | 0.00% | – |
| Q1 2020 | $2,002,000 | +15.1% | 163,680 | +38.0% | 0.00% | – |
| Q4 2019 | $1,740,000 | -1.3% | 118,623 | -10.2% | 0.00% | – |
| Q3 2019 | $1,763,000 | -78.1% | 132,048 | -73.1% | 0.00% | -100.0% |
| Q2 2019 | $8,043,000 | +303.2% | 491,295 | +320.6% | 0.00% | – |
| Q1 2019 | $1,995,000 | +1.9% | 116,809 | -18.6% | 0.00% | – |
| Q4 2018 | $1,958,000 | -52.7% | 143,435 | -0.9% | 0.00% | -100.0% |
| Q3 2018 | $4,143,000 | -30.2% | 144,743 | -33.3% | 0.00% | 0.0% |
| Q2 2018 | $5,939,000 | -17.2% | 217,100 | -36.2% | 0.00% | -33.3% |
| Q1 2018 | $7,177,000 | +163.6% | 340,300 | +140.2% | 0.00% | +200.0% |
| Q4 2017 | $2,723,000 | -35.9% | 141,693 | -17.1% | 0.00% | 0.0% |
| Q3 2017 | $4,247,000 | +352.3% | 170,878 | +191.1% | 0.00% | – |
| Q2 2017 | $939,000 | +162.3% | 58,700 | +131.1% | 0.00% | – |
| Q1 2017 | $358,000 | -24.9% | 25,400 | -30.2% | 0.00% | – |
| Q4 2016 | $477,000 | – | 36,415 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Discovery Value Fund | 561,561 | $17,756,559 | 9.73% |
| MPM BioImpact LLC | 544,639 | $17,221,485 | 4.60% |
| Casdin Capital, LLC | 1,178,075 | $37,250,732 | 4.12% |
| HIMENSION CAPITAL (SINGAPORE) PTE. LTD. | 1,145,091 | $36,207,777 | 3.72% |
| Atlas Venture Associates IX, LLC | 10,000 | $316,200 | 2.69% |
| Deep Track Capital, LP | 2,000,000 | $63,240,000 | 2.44% |
| ARK Investment Management | 9,948,629 | $314,575,638 | 2.41% |
| Merlin Capital, Inc | 18,526 | $585,792 | 2.19% |
| Orchard Capital Management, LLC | 159,155 | $5,032,481 | 1.86% |
| TANG CAPITAL MANAGEMENT LLC | 397,600 | $12,572,112 | 1.77% |